Tier 4 — mechanistic

New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463

Yi Zhu, Ewald J. Doornebal, Tamar Pirtskhalava, Nino Giorgadze, Mark Wentworth, Heike Fuhrmann-Stroissnigg, Laura J. Niedernhofer, Paul D. Robbins, Tamara Tchkonia, James L. Kirkland

AGING 2017 Vol. 9, No. 3, pages 955-963

Bibliography

DOI: 10.18632/aging.101202
PubMed: PMID 28273655
PubMed Central: PMC5391241
Funding: This work was supported by NIH grant R37AG013925 (J.L.K.), P01AG043376 (Project 2 and Core A: P.D.R., Project 1 and Core B: L.J.N.), the Connor Group, and the Noaber and Ted Nash Foundations (J.L.K.).
Competing interests: YZ, TP, NG, TT, JLK, and Mayo Clinic have a financial interest related to this research. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic conflict of interest policies.

Study snapshot

Design	Preclinical in vitro cell culture study
Model	Human umbilical vein endothelial cells (HUVECs), IMR90 human lung fibroblasts, and primary human preadipocytes
Sample	Primary human preadipocytes from 4 healthy lean subjects; 5 replicates per assay for cell lines
Intervention	In vitro exposure to the flavone fisetin (up to 80 µM) or BCL-XL inhibitors (A1331852, A1155463)
Duration	Up to 3 days (72 hours) for viability assays; 12 hours for caspase activity assays
Endpoints	Cell viability (ATPLite), viable cell numbers (crystal violet), and apoptosis induction (caspase 3/7 activity)

What the study showed, in plain terms

As we age, a subset of our cells stops dividing but refuses to die. These "senescent" cells secrete inflammatory signals that damage surrounding tissues and drive aging. Researchers are actively searching for "senolytics"—compounds that selectively destroy these toxic cells while leaving healthy cells alone.

This study investigated fisetin (a natural flavonoid found in strawberries) alongside two targeted synthetic drugs (A1331852 and A1155463). The researchers treated various human cells grown in a lab to see if these agents could selectively eliminate the senescent cells by disabling their survival pathways.

Fisetin successfully and selectively cleared senescent human umbilical vein endothelial cells (HUVECs). However, it did not clear senescent lung fibroblasts or fat cell progenitors (preadipocytes). This indicates that while fisetin is a promising senolytic, its effectiveness is highly specific to certain cell types.

Key findings

Targeted Senolytic Activity: Fisetin successfully induced apoptosis (programmed cell death) in senescent Human Umbilical Vein Endothelial Cells (HUVECs) without harming healthy, proliferating HUVECs.
Cell-Type Specificity: Fisetin did not act as a senolytic in IMR90 human lung fibroblasts or primary human preadipocytes, showing that senescent cell vulnerability varies significantly by tissue origin.
Effective Dosages: In endothelial cells, fisetin triggered cell death pathways (caspase 3/7 activity) at concentrations as low as 0.5 μM and reduced senescent cell viability at 5-10 μM over a 72-hour period.
Survival Pathway Validation: The synthetic inhibitors A1331852 and A1155463 successfully cleared senescent HUVECs and IMR90 cells, confirming that inhibiting the BCL-XL survival pathway is a viable cellular clearance strategy.

What this study can and cannot tell us

In Vitro Scope: This study was conducted entirely on isolated cells in a laboratory (in vitro). These mechanistic findings require validation in living organisms (in vivo) to confirm systemic efficacy and safety.
Narrow Efficacy: Fisetin only demonstrated senolytic effects in one specific cell line (HUVECs), indicating it may not clear senescent cells universally across all human organs.
Bioavailability Gaps: Direct cellular exposure in a controlled lab environment does not account for human digestion, metabolism, and tissue distribution of oral fisetin supplements.